 | | Imaging in Cardiovascular Disease |
|  | | Standard imaging biomarkers in cancer-FDG-PET/CT |
|
 | | Up-and-coming imaging biomarkers in cancer |
|  | | Utility of atherosclerosis imaging in the evaluation of drug therapies |
|
 | | Clinical non invasive imaging of plaques |
|  | | Why MRI & FDG-PET? |
|
 | | Moderate Carotid Artery Stenosis: MR Imaging– depicted-Intraplaque Hemorrhage Predicts Risk of Cerebrovascular Ischemic Events in Asymptomatic Men |
|  | | Incidence of cerebrovascular events between arteries with (MRIPH Positive) and those without (MRIPH Negative) MR-depicted IPH |
|
 | | Fe3O4 |
|  | | Sosnovik D et al. Basic Res Cardiol. 2008 March; 103(2): 122–130 |
|
 | | Risk factors associated with plaque characteristics seen on MRI in various population-based studies |
|  | | FDG-PET/CT detection of plaque |
|
 | | Up-regulation of Glycolysis and Glycolytic Genes With Classic/Innate But Not Alternative Activation |
|  | | FDG Uptake By Macrophages |
|
|  | | Measuring atherosclerosis FDG-PET/CT |
|
 | | First multi-center RCT w statins |
|  | | Effect of P38 MAP Kinase Inhibition on Vascular FDG Uptake |
|
 | | First multi-center multimodal RCT |
|  | | Sample MRI Images from a patient at baseline and treated with dalcetrapib 600 mg for 24 Months showing regression in Total Vessel Area (TVA) |
|
 | | Coronary FDG PET |
|  | | Vascular FDG signal identifies future atherothrombotic events |
|
 | | Imaging intraplaque inflammation in carotid atherosclerosis with 11C-PK11195 PET/CT |
|  | | 18F-sodium fluoride activity in the aortic valve – active calcification marker? |
|
 | | 1st MR/PET Whole-Body System (Dec 2009): Integration of low-radiation high-contrast & metabolic information |
|  | | • CT limited to photon absorption by tissue or contrast medium |
|
 | | RECENT MR/PET hardware developments |
|  | | Spectral CT with energy-resolving detector |
|
 | | Multicolor molecular CT imaging |
|  | | Multicolor/Spectral CT photon counting imaging |
|
|  | | Cardiovascular nanotechnology: the opportunity |
|
 | | Osborn EA & Jaffer F JACC Imaging 2012 |
|  | | HDL: a contrast/drug delivery platform |
|
 | | Nanoparticle – Drug Delivery |
|  | | High Risk Patients: New Treatment Paradigm |
|
 | | Nanoparticle (NP)-glucocorticoids (1 injection) with imaging used to evaluate efficacy - FDG-PET/CT |
|  | | 1st in man trial with glucocorticoids liposomes for atherosclerosis treatment@AMC, Netherlands |
|
 | | Statins have high liver uptake and low bioavailability to atherosclerotic macrophages |
|  | | Statin loaded rHDL nanoparticles ([S]-rHDL) target atherosclerotic macrophages |
|
 | | Summary |
|
Deel deze pagina met collega's en vrienden: